With next generation of complex immuno-oncology candidates, preclinical and translational scientists in the IO space are in need for more predictive tumour models to improve clinical translatability, accelerating speed-to-clinic with confidence.

We are excited to finally reunite this community in December at 11th PREDiCT: Tumour Models London Summit to address the critical next step of narrowing the preclinical gap and progressing efficacious candidates to the clinic.

This much-anticipated in-person meeting will unite 120+ pioneers to help you:

Benchmark against peers' in vivo and in vitro model selection strategy for novel IO, in conjunction with NK and macrophages interaction with TME, to maximise translatability

Evaluate and compare next generation tumour models for TME, cell-cell interaction, immune response and drug response to guide clinical design and patient selection

Accelerate off-the-shelf humanised and PDX model development for NK, allogenic cell therapies

Rigorously test, characterise, validate novel cancer models to support adoption and ensure quality control in preclinical studies

Engage with leading academics and CROs to drive long-term partnerships and fuel model innovations

This is your must-attend tumour model summit to reconnect with fellows from Pfizer, Sanofi, GSK, and propel your clinical progression with confidence in 2023!

Continue reading at tumour-models.com

Oncology

Facebook Share

Twitter Share

Linkedin Share

Email Share